TGFB1 and neoplasm: This metabolic shift promotes an M2-like phenotype characterized by elevated immunosuppressive cytokine secretion (e.g., IL-10, TGF-β) and reduced anti-tumor immunity, as evidenced by decreased cytotoxic CD8+ T-cell infiltration.